Anika Therapeutics NASDAQ: ANIK CEO Steve Griffin outlined the company’s strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line growth, a differentiated hyaluronic acid-based technology platform, and continued investment in its pipeline.
Company positioning and financial profile
Griffin said Anika has operated for 33 years with a primary focus on hyaluronic acid (HA) technologies spanning osteoarthritis (OA) pain management and regenerative medicine. He described the business as generating “strong profitability” and “strong cash flow,” supported by a balance sheet with more than $50 million in cash and no debt.
Griffin also referenced recent results, stating the company “just announced” its results last week, including positive EBITDA and positive free cash flow in 2025. He said Anika generated about $5 million of adjusted EBITDA and more than $11 million of operating cash flow in 2025.
Portfolio overview and total addressable market
Anika’s business is organized into two primary portfolios:
- OA Pain Management: Orthovisc, Monovisc, and Cingal (viscosupplement injection products)
- Regenerative Solutions: Integrity and Hyalofast (built on the company’s HYAFF technology)
Griffin framed the company’s overall opportunity set as a total addressable market (TAM) of more than $3 billion, and provided TAM estimates for several categories:
- Monovisc and Orthovisc: more than $1 billion TAM
- Integrity Implant System: roughly $230 million TAM in the U.S. (Griffin also referenced “about a $200 million” opportunity in discussing the product)
- Hyalofast (U.S. opportunity): more than $1 billion TAM
- Cingal: another $1 billion of TAM potential, which Griffin characterized as a next-generation OA pain management product
Core OA business: Orthovisc and Monovisc
Griffin highlighted Orthovisc and Monovisc as the company’s core products in the U.S. visco injection market. He said the products deliver long-lasting pain relief—effective for more than six months—whether through Monovisc’s single-injection regimen or Orthovisc’s multi-injection approach. He characterized them as high molecular weight products manufactured in Bedford, Massachusetts, and said they form a “core profitable” base that generates strong free cash flow.
In the U.S., Anika sells Orthovisc and Monovisc through Johnson & Johnson’s DePuy, which Griffin described as a long-standing relationship of more than 10 years. Outside the U.S., Anika sells Orthovisc and Monovisc through its direct commercial channel using country-level and stocking-level distributors across more than 40 countries, which Griffin said has produced consistent growth.
Regenerative Solutions: Integrity and Hyalofast
Griffin described the Integrity Implant System as a newer product line. The Integrity tendon augmentation patch, launched in the U.S. in 2023, is based on Anika’s HYAFF technology (a bioabsorbable esterified hyaluronic acid biopolymer). He said Integrity is designed to retain strength even when wet, is soft and pliable while retaining sutures, and can be used arthroscopically with Anika’s instrumentation. Griffin positioned Integrity as differentiated from collagen-based implants on the market.
On commercialization, Griffin said Integrity generated about $2 million in 2024 sales and about $6 million in 2025 sales, and that performance was ahead of initial launch expectations. While the company has some limited sales outside the U.S., he said the primary market has been the U.S. through Anika’s own commercial channel.
Griffin also discussed Hyalofast, a cartilage repair product sold outside the U.S. in more than 35 countries. He said the company has more than 15 years of clinical data outside the U.S. and has implanted more than 40,000 units for cartilage repair. He emphasized Hyalofast as a single-stage surgery product that can be held “on the shelf,” and said this is differentiated compared to other approaches.
On the U.S. regulatory pathway, Griffin said Anika submitted a PMA to the FDA and completed the third module of its filing in the fourth quarter of last year, entering “back-and-forth discussions” with the agency regarding clinical data. He noted that the company did not meet its co-primary pre-specified endpoints, but did demonstrate statistical significance on secondary endpoints. Griffin said Anika believes that, together with its international data, will be important in discussions with the FDA as it seeks U.S. approval. He also referenced Vericel’s MACI as a well-known competitor in the U.S. cartilage market and said Anika is currently planning a U.S. launch through its commercial channel if approved.
Pipeline and growth strategy: Cingal, channel mix, and 2026 outlook
Griffin presented Cingal as a combination product pairing triamcinolone hexacetonide (a fast-acting steroid) with Monovisc. He said Cingal has completed three Phase 3 trials demonstrating statistical significance versus placebo, Monovisc alone, and triamcinolone hexacetonide. Griffin also said the product has been used in more than 1 million patient injections internationally since launch.
Regarding the U.S. pathway, Griffin said Anika is working with the FDA toward an NDA submission and has been clarifying the filing pathway over time. He cited two prerequisites before filing: toxicity studies (completed successfully in 2025) and a bioequivalent study for the triamcinolone hexacetonide component (initiated at the end of last year). He said the company expects to file an NDA after completing the bioequivalent study and CMC preparations.
Griffin framed Anika’s revenue base through two channels:
- OEM channel: primarily U.S. Monovisc and Orthovisc sales through J&J MedTech, described as high margin and free cash flow generative, but pressured by U.S. pricing changes
- Commercial channel: international OA pain products across more than 40 countries, plus Hyalofast outside the U.S. and the U.S. Integrity launch
He said the OEM channel has been challenging over the past year due to U.S. pricing dynamics, contributing to a decline in 2025 revenue. For 2026, Griffin said he expects the OEM business to be flat to modestly lower, with volume increases—especially Monovisc—offset by pricing pressure.
In contrast, Griffin said the commercial channel has delivered consistent growth, citing 17% annual top-line increases over the last five years and growth from $26 million in 2021 to $48 million in 2025. He said Anika expects the commercial channel to grow again in the “mid-teens” and provided 2026 guidance of 10% to 20% revenue growth for the commercial channel. He said international OA pain and international regenerative products are expected to grow in the low double digits and drive most of the dollar increase, while the U.S. regenerative business—primarily Integrity—is expected to contribute the largest year-over-year variance increase in 2026.
On profitability, Griffin said adjusted EBITDA in 2026 is expected to be 5% to 10% of revenue, driven by top-line growth and additional cost-out actions tied to leadership changes, partially offset by pricing impacts in the OEM business.
During the Q&A, Griffin responded to a question about R&D investment amid a competitive and mature HA market. He said Anika’s R&D efforts on the OA side are “specifically related” to Cingal, which he described as the company’s next generation OA pain product for the U.S. He added that additional R&D efforts are focused on the HYAFF side of the business, including Integrity, Hyalofast, and other pipeline concepts that were not discussed in detail.
About Anika Therapeutics NASDAQ: ANIK
Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika's proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company's core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
